- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01430091
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
5 octobre 2012 mis à jour par: Eli Lilly and Company
Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects
This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally.
The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
18
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 65 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Overtly healthy males or females, as determined by medical history and physical examination
- Are either women who are of child-bearing potential, surgically sterilised or defined as post-menopausal. Female subjects of child-bearing potential (not surgically sterilised between menarche and menopause) must have a negative pregnancy test at the time of screening and must be using a reliable method of birth control. These include tubal ligation, an intrauterine device which has been in place for at least 3 months, the oral contraceptive pill which has been taken, without difficulty, for at least 3 months, or an approved hormonal implant. Barrier methods alone (condoms or diaphragm/cap) are not acceptable, but must be used in conjunction with a chemical method, that is, spermicidal gel. A woman is presumed to be post-menopausal if she has had amenorrhoea for greater than 12 months alone or amenorrheic for 6 to 12 months and has a serum oestradiol concentration <73 picomoles per liter (pmol/L) (20 picograms per milliliter [pg/mL]) (not applicable for women on hormone replacement therapy [HRT; oestrogen]) and a follicle stimulating hormone (FSH) concentration >40 international units per liter (IU/L).
- Have clinical laboratory test results within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Between the body mass index (BMI) of 18.5 and 32.0 kilograms per meter squared (kg/m^2), inclusive
- Have acceptable blood pressure (BP) and heart rate (HR) (supine) as determined by the investigator
- Have venous access sufficient to allow blood sampling
- Are reliable and willing to make themselves available for the duration of the study, and will abide by the research unit policy and procedure and study restrictions
- Have given written informed consent approved by Lilly and the Ethical Review Board (ERB) governing the site
Exclusion Criteria:
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data, as determined by the investigator
- Evidence of significant active neuropsychiatric disease
- Have a history or presence of significant bleeding disorders, that is, haematemesis, melaena, severe or recurrent epistaxis, haemoptysis, haemorrhage, clinically overt haematuria, or intracranial haemorrhage
- Have a history (within the last 5 years) or presence of gastric ulcers. Previous history of duodenal ulcer is acceptable but must have been successfully surgically or medically treated with no further evidence of disease in the past 6 months (from screening)
- Have a personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations, for example, cerebral haemorrhage, aneurysm, or premature stroke (cerebrovascular accident <65 years of age)
- Have a self-reported history of significant bleeding from trauma (for example, prolonged bleeding after tooth extraction)
- Are pre-menopausal females with a history or presence of menorrhagia within the last 5 years (from screening)
- Have clinically significant out of range values for prothrombin time (PT), activated partial thromboplastin time (APTT), or platelet count at screening
- Have repeatedly reported positive results (at least 2 separate samples) on the faecal occult blood examination
- Have a history of major surgery within 3 months of screening
- Have planned surgery within 14 days after the last study day
- Have a clinically significant abnormality in fundoscopic examination or petechiae examination
- Have any other clinically significant abnormality following the investigator's review of the prestudy physical examination, electrocardiogram (ECG) and clinical (safety) laboratory tests
- Regularly use known drugs of abuse and/or show unacceptable positive findings on urinary drug screening
- Have known allergies or significant hypersensitivity to prasugrel or related drugs, or a history of relevant allergic drug reactions of any origin
- Have donated blood of more than 500 mL within the previous 1 month before prasugrel administration
- Show evidence of positive human immunodeficiency virus (HIV) antibodies
- Show evidence of positive hepatitis C antibody
- Show evidence of positive hepatitis B surface antigen
- Have a regular alcohol intake greater than 21 units/week for males or 14 units/week for females or are unwilling to comply with the alcohol consumption requirements from 48 hours prior to the first dose of prasugrel until discharge from the clinical research unit (CRU) after the final Pharmacokinetics (PK) sample of Period 5 has been taken. One unit of alcohol is equal to 8 g ethanol
- Smoke 10 or more cigarettes per day
- Use prescription, over the counter or herbal medications that cannot safely be discontinued within 14 days prior to prasugrel administration. Exceptions: subjects may continue thyroid replacement therapy, HRT (oestrogen), contraceptives and certain medications that are inhaled or applied to the skin, eyes, or nose. The influenza vaccine may also be administered; however this must be at least 72 hours before any prasugrel dose
- Use proton pump inhibitors, antacids, or H2 antagonists, which may impact stomach pH
- Have participated in a study involving administration of an investigational compound within the 30 days prior to prasugrel administration
- Have any other condition that, in the opinion of the principal investigator increases the risk to the study subject or decreases the likelihood of obtaining reliable results from the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Prasugrel clinical formulation
A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
|
Administered orally
Autres noms:
|
Expérimental: Prasugrel (ODT) - on tongue
A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
|
Administered orally
Autres noms:
|
Expérimental: Prasugrel (ODT) - apple juice
A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
|
Administered orally
Autres noms:
|
Expérimental: Prasugrel (ODT) - chewed
A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
|
Administered orally
Autres noms:
|
Expérimental: Prasugrel (ODT) - under tongue
A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
|
Administered orally
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel's Active Metabolite (PRAS-AM)
Délai: Pre-dose up to 8 hours post-dose after each treatment
|
Pre-dose up to 8 hours post-dose after each treatment
|
Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel's Active Metabolite (PRAS-AM)
Délai: Pre-dose up to 8 hours post-dose after each treatment
|
Pre-dose up to 8 hours post-dose after each treatment
|
Pharmacokinetics: Time of Maximum Concentration (Tmax) of Prasugrel's Active Metabolite (PRAS-AM)
Délai: Pre-dose up to 8 hours post-dose after each treatment
|
Pre-dose up to 8 hours post-dose after each treatment
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 septembre 2011
Achèvement primaire (Réel)
1 octobre 2011
Achèvement de l'étude (Réel)
1 octobre 2011
Dates d'inscription aux études
Première soumission
6 septembre 2011
Première soumission répondant aux critères de contrôle qualité
6 septembre 2011
Première publication (Estimation)
7 septembre 2011
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
6 novembre 2012
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 octobre 2012
Dernière vérification
1 octobre 2012
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 13040
- H7T-EW-TADQ (Autre identifiant: Eli Lilly and Company)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Drépanocytose
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRecrutementÉligible en hématopathologie ou traitement CAR-t CellFrance
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRecrutementMesures des résultats rapportés par les patients | Thérapie CAR T-CellSuisse
-
Dartmouth-Hitchcock Medical CenterComplétéLymphome | Leucémie | Myélome multiple | Greffe de cellules souches | Greffe de cellules souches hématopoïétiques | Thérapie CAR T-Cell | GCSH | Thérapie cellulaire | Transplantation CAR T-CellÉtats-Unis
-
Shenzhen Fifth People's HospitalRecrutement
-
Manchester University NHS Foundation TrustUniversity of Manchester; The Christie NHS Foundation Trust; Zenzium AI Ltd.; Aptus... et autres collaborateursRecrutementCancer colorectal | Cancer du poumon | Cancer hématologique | Thérapie CAR T-CellRoyaume-Uni
-
Sun Yat-sen UniversityPas encore de recrutementCancer du col de l'utérus | Effet de la chimiothérapie | Thérapie néoadjuvante | Programmed Cell Death 1 Receptor / Antagonistes et inhibiteurs
-
University of Alabama at BirminghamRésiliéLymphome anaplasique à grandes cellules | Lymphome T angio-immunoblastique | Lymphomes T périphériques | Leucémie à cellules T de l'adulte | Lymphome T adulte | Lymphome T périphérique Non précisé | T/Null Cell Systemic Type | Lymphome cutané à cellules T avec maladie nodale/viscéraleÉtats-Unis
-
Adelphi Values LLCBlueprint Medicines CorporationComplétéLeucémie mastocytaire (MCL) | Mastocytose systémique agressive (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Mastocytose systémique fumante (SSM) | Mastocytose systémique indolente (ISM) Sous-groupe ISM entièrement recrutéÉtats-Unis
-
The First Affiliated Hospital of Xiamen UniversityRecrutementCarcinome réfractaire de la glande thyroïde | Carcinome papillaire de la glande thyroïde réfractaire | Carcinome folliculaire de la glande thyroïde réfractaire | Carcinome réfractaire de la glande thyroïde Hurthle CellChine
-
National Cancer Institute (NCI)ComplétéCarcinome différencié de la glande thyroïde réfractaire | Carcinome de la glande thyroïde non résécable | Carcinome papillaire de la glande thyroïde réfractaire | Carcinome folliculaire de la glande thyroïde réfractaire | Carcinome réfractaire de la glande thyroïde Hurthle CellÉtats-Unis, Canada
Essais cliniques sur Prasugrel (clinical formulation)
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; Clinical Innovations, LLCRecrutementComplications de la césarienne | Obésité morbideÉtats-Unis
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.ComplétéVolontaires en bonne santéÉtats-Unis
-
DascenaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Baystate Health; Cape Regional Medical Center et autres collaborateursRecrutementÉtat septique | Choc septique | Septicémie sévèreÉtats-Unis
-
Gyeongsang National University HospitalComplétéSaignement | Syndrome coronarien aigu | Thromb plaquettaireCorée, République de
-
University of FloridaComplété
-
University of MilanComplété
-
University of PatrasComplété
-
University of FloridaComplétéMaladie de l'artère coronaireÉtats-Unis
-
Medstar Health Research InstituteComplétéSyndrome coronarien aiguÉtats-Unis
-
VA Office of Research and DevelopmentComplétéPontage coronarienÉtats-Unis